Log In
BCIQ
Print this Print this
 

SNA-125 (formerly CT340)

  Manage Alerts
Collapse Summary General Information
Company Sienna Biopharmaceuticals Inc.
DescriptionTopical neurotrophic tyrosine kinase receptor 1 (TrkA; NTRK1) and janus kinase-3 (JAK-3) inhibitor
Molecular Target Neurotrophic tyrosine kinase receptor 1 (TrkA) (NTRK1) ; Janus kinase-3 (JAK-3)
Mechanism of Action 
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$150.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/06/2016

Undisclosed

Undisclosed

$150.0M

Get a free BioCentury trial today